Peter Casaer/MSF
Kadia, 20 years old, tested positive for Ebola and was offered the choice to be enrolled in the favipiravir trial, a new antiviral that is being tested for efficacy and safety in the ETC of Guéckédou.
She receives the full information about Ebola, the favipiravir and the trial modalities by a member of the MSF team and can choose to participate in the trial or if she prefers to receive standard of care alone.
Kadia accepted to take favipiravir and less than 2 weeks later she was cured and discharged. She returned home to her only surviving child – her husband and other child have passed away.